Single-nucleotide polymorphisms of donor CYP3A5 and recipient ABCB1 affect tacrolimus intrapatient variability in living donor liver transplantation: a retrospective cohort study
10.4174/astr.2025.109.4.252
- Author:
Saran Ochir GONGOR
1
;
Kwang-Woong LEE
;
Eun-Woo CHOI
;
Jae-Yoon KIM
;
Jeong-Moo LEE
;
Suk Kyun HONG
;
YoungRok CHOI
;
Nam-Joon YI
;
Kyung-Suk SUH
Author Information
1. Department of Surgery, Seoul National University College of Medicine, Seoul, Korea
- Publication Type:ORIGINAL ARTICLE
- From:Annals of Surgical Treatment and Research
2025;109(4):252-260
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:The relationship between tacrolimus intrapatient variability (IPV) and its metabolism-associated singlenucleotide polymorphisms (SNPs) in liver transplantation (LT) remains unclear. Moreover, the influence of donor SNP on recipient IPV is poorly understood. Our objective was to investigate how SNPs affect tacrolimus IPV by analyzing both donor and recipient SNP data in LT.
Methods:This retrospective study examined the association between tacrolimus IPV and eight specific SNPs in 50 adult LT recipients and 50 LT donors genotyped for CYP3A5, ABCB1, ABCC2, and POR genes and their SNPs. Recipients were divided into high IPV (≥30) and low IPV (<30) groups based on 3–12 months after LT IPV calculations. Multivariate logistic regression was used to identify risk factors for high IPV. Post-LT long-term outcomes were also compared between the groups.
Results:Two SNPs were significantly associated with high IPV in multivariate analysis. Recipient ABCB1 1236C>T genotypes CT and CC (odds ratio [OR], 13.969; 95% confidence interval [CI], 1.738–112.300; P = 0.013), donors’ CYP3A5 6986A>G genotypes GA and GG (OR, 4.390; 95% CI, 1.005–19.178; P = 0.049), and glucose ≥120 mg/dL at 3 months (OR, 6.494; 95% CI, 1.300–32.168; P = 0.024) were associated with high IPV. However, post-LT long-term outcomes were similar between the groups.
Conclusion:SNPs of donor CYP3A5 and recipient ABCB1 can significantly influence tacrolimus IPV in patients undergoing living donor LT. Identifying these SNPs can help determine high IPV-prone patients, facilitate close monitoring of high IPVsusceptible groups, and improve outcomes.
